2025 年 07 月 20 日 药明康德(603259.SH) 核心管线厚积薄发，一体化 CRDMO 龙头 砥砺奋进再起航 小分子 D&M 业务：项目管线持续扩张，相关业务稳健发展 公司凭借着自身丰富的客户资源和项目管线储备，以及稳定的大规模 生产能力，驱动小分子 D&M 业务的稳步发展。其中，项目管线方面， 公司 D&M 管线总数从 2021 年的 1666 个稳步增长至 2025Q1 的 3393 个，商业化项目从 2021 年的 42 个稳步增长至 2025Q1 的 75 个；产能 建设方面，2024 年泰兴原料药生产基地投入运营，常州和泰兴的产 能持续稳步提升，预计 2025 年末小分子原料药反应釜体积有望超 4000kL。此外，美国米德尔顿基地、新加坡研发和生产基地持续推进 建设，预计分别于 2026 年末和 2027 年逐步投入运营。 TIDES 业务：受益于多肽行业高景气，相关业务有望高增长 GLP-1 重磅药物销售有望快速放量，有望持续推动肽类 CDMO 需求提 升。其中，替尔泊肽销售从 2022 年的 4.83 亿美元快速增长至 2024 年的 164.66 亿美元，CAGR 高达 484 ...

Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing significant growth, particularly in innovative drugs, with many companies seeing their stock prices double [1]. Group 1: Market Dynamics - The listing of TIDE Pharmaceutical (03880.HK) on June 30 attracted considerable market attention, with a subscription rate of 301.15 times for public offerings and 2.43 times for international offerings [2]. - TIDE Pharmaceutical is positioned in a favorable market window, driven by two core market dynamics: the global capital market's shift towards Chinese technology assets and the upcoming results in China's innovative drug industry by 2025 [3][4]. Group 2: Industry Growth Potential - The global peptide drug market is projected to reach $261.2 billion by 2032, with a compound annual growth rate (CAGR) of 12.6% [7]. - In China, the GLP-1 drug market is expected to grow from $100 million in 2018 to $1.3 billion in 2023, with a CAGR of 65.3%, and further to $23.2 billion by 2032, with a CAGR of 37.3% [11]. - TIDE Pharmaceutical is strategically focusing on the GLP-1 sector, which is becoming a major trend in the pharmaceutical industry [7]. Group 3: Competitive Positioning - TIDE Pharmaceutical is recognized as the third-largest peptide CRDMO globally, with nine GLP-1 molecule development projects and partnerships with seven clients [15]. - The company is expanding its production capacity, with facilities in Hangzhou and the U.S., to meet the anticipated surge in market demand [16]. Group 4: Technological Advancements - TIDE Pharmaceutical has over 20 years of experience in the peptide CRDMO industry, with a strong team of experts and a wealth of knowledge in peptide drug design and synthesis [18]. - The company utilizes multiple proprietary technology platforms, including OmniPeptSynth™ and PeptiNuclide LinkTech™, to enhance its innovation capabilities [19][20]. - TIDE's long-term service capabilities have earned recognition from pharmaceutical companies, further solidifying its position in the peptide drug sector [21]. Group 5: Future Outlook - TIDE Pharmaceutical is well-positioned to benefit from the upcoming expiration of patents for major GLP-1 drugs, which will create significant demand for generic APIs [23]. - The company is also exploring opportunities in the oligonucleotide drug sector, indicating a broad market potential [23]. - Overall, TIDE Pharmaceutical's strategic positioning and technological expertise suggest strong long-term growth potential in the innovative drug market [22].

Core Viewpoint - The article highlights the strong performance of three newly listed stocks in the Hong Kong market, particularly IFBH, which has seen significant demand and price appreciation in the dark market trading phase, indicating a bullish sentiment in the consumer sector [1][2]. Company Overview - IFBH is a Thailand-based company specializing in ready-to-drink beverages and ready-to-eat foods, known for its if brand, which is a leader in the coconut water market in mainland China [3]. - The company was founded in 2013 and has undergone a business restructuring to focus on its international operations, particularly the if and Innococo brands, to meet growing global demand [3][4]. Business Model and Operations - IFBH operates on a light-asset model, employing only 46 staff members, with a focus on marketing, logistics, and minimal administrative roles [4]. - The company relies entirely on third-party manufacturers for product production, allowing it to concentrate on brand development and market expansion [3][4]. Market Position and Performance - IFBH holds the top position in the coconut water beverage market in mainland China with a market share of approximately 34% as of 2024, significantly outpacing its nearest competitor [5]. - In Hong Kong, IFBH also leads the coconut water market with a market share of about 60% [5]. - Globally, IFBH ranks as the second-largest coconut water beverage company, demonstrating impressive growth rates and a gross margin increase from 34.7% in 2023 to 36.7% in 2024 [6]. Financial Metrics - The net profit margin for IFBH improved from 19.2% in 2023 to 21.1% in 2024, reflecting strong financial health and operational efficiency [7]. - The company attracted significant interest from cornerstone investors, including major financial institutions, indicating confidence in its growth potential [7]. Industry Context - The article notes a broader bull market for consumer stocks in Hong Kong, with notable price increases in various food and beverage companies, suggesting a favorable environment for new listings [7]. - Other companies listed alongside IFBH, such as 泰德医药 and 云知声, showed mixed performance in the dark market, with 泰德医药 focusing on peptide CRDMO services and 云知声 providing AI solutions [8][9].

Core Viewpoint - The article highlights the strong performance of IFBH, a well-known consumer company, in the recent IPO market, with a significant increase in its stock price, while the other two companies, Taide Pharmaceutical and Yunzhisheng, showed modest performance [1][21]. Group 1: IFBH Performance - IFBH's stock price surged over 60% in the dark market, making it the biggest winner among the three newly listed companies [1]. - The company achieved a subscription multiple of 2240 times, with a financing subscription amount reaching 2594.8 billion HKD [3][11]. - IFBH has a market share of approximately 34% in the coconut water beverage market in mainland China, leading the market for five consecutive years [12][16]. Group 2: Company Overview - IFBH, founded in 2013, specializes in ready-to-drink beverages and ready-to-eat foods, particularly coconut water, and is a leader in the Chinese market [11]. - The company operates on a light asset model, relying on third-party manufacturers for production, with only 46 employees as of the end of 2024 [12][13]. - IFBH's gross profit margin improved from 34.7% in 2023 to 36.7% in 2024, and its net profit margin increased from 19.2% to 21.1% during the same period [16][17]. Group 3: Competitors' Performance - Taide Pharmaceutical, a global leader in peptide-focused CRDMO, holds a market share of 1.5% and provides comprehensive services from early discovery to commercial production [21]. - Yunzhisheng, an AI solutions provider, ranks as the fourth largest AI solution provider in China with a market share of 0.6%, focusing on conversational AI products for daily life and medical applications [22][23]. - Both Taide Pharmaceutical and Yunzhisheng exhibited lackluster performance in the dark market, contrasting sharply with IFBH's success [1][21].